Therapy of advanced acute myeloblastic leukemia with cytarabine and interleukin 2.
A child with acute myelogenous leukemia who relapsed three months after an allogeneic bone marrow transplant received intermediate-dose cytarabine followed by interleukin 2 (IL-2). Complete remission was achieved after the first cycle of IL-2. Five more combined cycles of cytarabine and IL-2 were given over the next year, during which remission has persisted. IL-2 therapy affected serum tumor necrosis factor (TNF), interferon gamma (IFN gamma) and soluble IL-2 receptor (sIL-2r) levels. In vitro cytotoxicity against leukemia cell lines and recipient leukemia cells was also increased.
Butturini
A
A
Department of Pediatrics, University of Parma, Italy.
Bonilauri
E
E
Izzi
G
G
Croci
G
G
Franchi
F
F
Santucci
M A
MA
Tondelli
M T
MT
Castriota Scanderbeg
A
A
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001853:Bone Marrow / Q000473:pathology; D016026:Bone Marrow Transplantation; D002675:Child, Preschool; D003131:Combined Modality Therapy; D003561:Cytarabine / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007371:Interferon-gamma / Q000097:blood; D007376:Interleukin-2 / Q000008:administration & dosage*; D015470:Leukemia, Myeloid, Acute / Q000097:blood / Q000188:drug therapy* / Q000601:surgery; D008297:Male; D009504:Neutrophils / Q000187:drug effects
D007376:Interleukin-2; D003561:Cytarabine; D007371:Interferon-gamma